No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

被引:26
|
作者
Riggio, Oliviero [1 ,2 ]
Nardelli, Silvia [1 ]
Pasquale, Chiara [1 ]
Pentassuglio, Ilaria [1 ]
Gioia, Stefania [1 ]
Onori, Eugenia [1 ]
Frieri, Camilla [1 ]
Salvatori, Filippo Maria [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Clin Med, Ctr Diag & Treatment Portal Hypertens, Rome, Italy
[2] Sapienza Univ Roma, Dipartimento Med Clin, Ctr Riferimento Ipertens Portale, Gastroenterol 2, Viale Univ 37, I-00185 Rome, Italy
关键词
TIPS; Hepatic encephalopathy; Liver cirrhosis; Albumin; PARACENTESIS PLUS ALBUMIN; COVERED STENT GRAFTS; RISK-FACTORS; REFRACTORY ASCITES; VARICEAL HEMORRHAGE; RANDOMIZED-TRIAL; CIRRHOSIS; PLACEMENT; MORTALITY; VARIABLES;
D O I
10.1007/s11011-015-9713-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepatic encephalopathy (HE) is a major problem in patients submitted to TIPS. Previous studies identified low albumin as a factor associated to post-TIPS HE. In cirrhotics with diuretic-induced HE and hypovolemia, albumin infusion reduced plasma ammonia and improved HE. Our aim was to evaluate if the incidence of overt HE (grade II or more according to WH) and the modifications of venous blood ammonia and psychometric tests during the first month after TIPS can be prevented by albumin infusion. Twenty-three patients consecutively submitted to TIPS were enrolled and treated with 1 g/Kg BW of albumin for the first 2 days after TIPS followed by 0,5 g/Kg BW at day 4th and 7th and then once a week for 3 weeks. Forty-five patients included in a previous RCT (Riggio et al. 2010) followed with the same protocol and submitted to no pharmacological treatment for the prevention of HE, were used as historical controls. No differences in the incidence of overt HE were observed between the group of patients treated with albumin and historical controls during the first month (34 vs 31 %) or during the follow-up (39 vs 48 %). Two patients in the albumin group and three in historical controls needed the reduction of the stent diameter for persistent HE. Venous blood ammonia levels and psychometric tests were also similarly modified in the two groups. Survival was also similar. Albumin infusion has not a role in the prevention of post-TIPS HE.
引用
收藏
页码:1275 / 1281
页数:7
相关论文
共 50 条
  • [41] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang, Yang
    Fu, Sirui
    Cao, Bin
    Hao, Kenan
    Li, Yong
    Huang, Jianwen
    Shi, Wenfeng
    Duan, Chongyang
    Bai, Xiao
    Tang, Kai
    Yang, Shirui
    He, Xiaofeng
    Lu, Ligong
    HEPATOLOGY INTERNATIONAL, 2021, 15 (03) : 730 - 740
  • [42] Transjugular intrahepatic portosystemic shunt: an analysis of outcomes
    Kurmis, Timothy P.
    ANZ JOURNAL OF SURGERY, 2009, 79 (10) : 745 - 749
  • [43] Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation
    Helzberg, James H.
    Dai, Rui
    Muir, Andrew J.
    Wilder, Julius
    Lee, Tzu-Hao
    Martin, Jonathan G.
    Kim, Charles Y.
    Ronald, James
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2021, 32 (07) : 950 - +
  • [44] Clinical value of hemodynamic changes in diagnosis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
    Li, Wanyan
    Duan, Yayang
    Liu, Zhike
    Lu, Xiaofeng
    She, Jingwen
    Qing, Jing
    Zhang, Chaoxue
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (06) : 713 - 718
  • [45] Preoperative prediction of overt hepatic encephalopathy caused by transjugular intrahepatic portosystemic shunt
    Yang, Yang
    Liang, Xueqing
    Yang, Shirui
    He, Xiaofeng
    Huang, Mingsheng
    Shi, Wenfeng
    Luo, Junyang
    Duan, Chongyang
    Feng, Xinghui
    Fu, Sirui
    Lu, Ligong
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 154
  • [46] Reversal of hemolytic anemia and hepatic encephalopathy by transjugular intrahepatic portosystemic shunt occlusion
    Sindhu A. Abraham
    Current Treatment Options in Gastroenterology, 2000, 3 (2) : 105 - 109
  • [47] Spleen volume is associated with overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with portal hypertension
    Zhao, Chun-Juan
    Ren, Chao
    Yuan, Zhen
    Bai, Guo-Hui
    Li, Jin-Yu
    Gao, Long
    Li, Jin-Hui
    Duan, Ze-Qi
    Feng, Dui-Ping
    Zhang, Hui
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (07):
  • [48] Prevention of transjugular intrahepatic portosystemic stent shunt thrombosis
    Sauer, P
    Theilmann, L
    DIGESTION, 1998, 59 : 45 - 47
  • [49] Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt
    Yin, Liang
    Chu, Sen-Lin
    Lv, Wei-Fu
    Zhou, Chun-Ze
    Liu, Kai-Cai
    Zhu, Yi-Jiang
    Zhang, Wen-Yue
    Wang, Cui-Xia
    Zhang, Yong-Hui
    Lu, Dong
    Cheng, De-Lei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2875 - 2887
  • [50] Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
    Sturm, Lukas
    Bettinger, Dominik
    Giesler, Max
    Boettler, Tobias
    Schmidt, Arthur
    Buettner, Nico
    Thimme, Robert
    Schultheiss, Michael
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (09) : 1380 - 1390